Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: Results in 71 thyroidectomized patients

European Journal of Endocrinology

Volumn 141, Issue 5, 1999, Pages 468-474

  Niccoli Sire, Patricia ^a   Murat, Arnaud ^b   Baudin, Eric ^c   Henry, Jean François ^a   Proye, Charles ^d   Bigorgne, Jean Claude ^e   Bstandig, Bettina ^f   Modigliani, Elisabeth ^f   Morange, Sophie ^a   Schlumberger, Martin ^c   Conte Devolx, Bernard ^a  

^a TIMONE HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ADOLESCENT; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CHILD; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC SCREENING; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; PROPHYLAXIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 0032698735     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410468     Document Type: Article

References (27)

1. Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B et al. Sporadic medullary thyroid carcinoma of the thyroid: a retrospective analysis of 80 cases. Thyroid 1998 8 1039-1044.
2. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham GH, Jansen-Schillhorn Van Veen JM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. New England Journal of Medicine 1994 31 828-835.
3. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG & Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinology and Metabolism Clinics of North America 1996 25 1-25.
4. Gagel RF. Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. In Endocrine Neoplasms, pp 421-441. Amsterdam: Kluwer Academic Publishers, 1997.
5. Learoyd D, Marsh D, Richardson AL, Twigg S, Delbridge L & Robinson B. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Archives of Surgery 1997 132 1022-1025.
6. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 1996 276 1575-1579.
7. Heshmati HM, Gharib H, Khosla S, Abu-Lebdeh HS, Linsor NM & Thibodeau SN. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clinic Proceedings 1997 72 430-436.
8. Wells SA, Chi DD, Toshima K, Denhen LP, Coffin CM, Dowton SB et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Annals of Surgery 1994 220 237-250.
9. Skinner MA, DeBenedetti MK, Moley JF, Norton JA & Wells SA. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. Journal of Pediatric Surgery 1996 31 177-182.
10. Leger GA, Khosla S, Lindor NM, Thibodeau SN & Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type 2. Annals of Internal Medicine 1995 122 118-124.
11. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995 118 1031-1035.
12. Murat A, Modigliani E, Conte-Devolx B, Rohmer V, Leclerc L, Guilhem I et al. Prise en charge thérapeutique précoce des sujets prédisposés génétiquement au cancer médullaire de la thyroide. Annales de Chirurgie 1998 52 455-460.
13. Wells SA & Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Experimental and Clinical Endocrinology and Diabetes 1998 106 29-34.
14. Lallier M, St-Vil D, Giroux M, Huot C, Gaboury L, Oligny L et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. Journal of Pediatric Surgery 1998 33 846-848.
15. Barbot N, Calmettes C, Schuffenecker I, St Andre JP, Franc B, Rohmer Vet al. Pentagastrin stimulation test and early diagnosis of MTC using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary MTC. Journal of Clinical Endocrinology and Metabolism 1994 78 114-120.
16. Wion-Barbot N, Schuffenecker I, Niccoli P, Conte-Devolx B, Lecomte P, Houdent C et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and FMTC. Annales d'Endocrinologie 1997 58 302-308.
17. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O et al. Sex related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. Journal of Clinical Endocrinology and Metabolism 1997 82 42-47.
18. Frilling A, Dralle H, Eng C, Raue F & Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995 118 1099-1104.
19. Frank-Raue K, Höppner W, Buhr H, Herfarth CH, Ziegler R & Raue F. Application of genetic screening in families with hereditary medullary thyroid carcinoma. Experimental Clinical Endocrinology and Diabetes 1996 104 108-110.
20. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS & Van Heerden JA. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995 118 936-942.
21. Gill JR, Reyes-Mugica M, Lyengar S, Kidd KK, Touloukian RJ, Smith C et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. Journal of Pediatrics 1996 129 459-463.
22. Proye C & Marmouzez T. Cancer médullaire de la thyroïde: moyens thérapeutiques, chirurgie de première intention. In Medullary Thyroid Carcinoma, pp 199-206. Eds C Calmettes & JM Guliana. Paris: John Libbey Eurotext, 1991.
23. Dralle H, Scheumann GFW, Proye C, Bacourt F, Frilling A, Limbert E et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. Journal of Internal Medicine 1995 238 357-361.
24. Decker RA, Geiger JD, Cox CE, Mackovjak M, Minakshi S & Peacock ML. Prophylactic surgery for MEN 2A after genetic diagnosis: is parathyroid transplantation indicated? World Journal of Surgery 1996 20 814-821.
25. 5 Telander RL, Zimmermann D, Sizemore GW & Van Heerden JA. Medullary thyroid carcinoma in children. Results of early detection and surgery. Archives of Surgery 1989 124 841-845.
26. Proye C, Carnaille B & Vandhoove L. Morbidity of total thyroidectomy in children and teenagers less than 15 years of age. Annales d'Endocrinologie 1998 59 93-98.
27. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World Journal of Surgery 1998 22 744-751.